While a larger sample size from collaborative studies is warranted to confirm the validity of the current findings, our data urge the importance of concurrent TP53 mutation and deletion analysis in pediatric AML patients for refined prognostication and guiding management. Here, TP53 is linked to acute myeloid leukemia.